PND25 Costs Associated with the Use of Enzyme-Inducing Anti-Epileptic Drugs Versus Non-Enzyme-Inducing Anti-Epileptic Drugs: A Systematic Review  by Xiong, T. et al.
A394  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
Embase, Scielo and LILACS using the key words “multiple sclerosis” and “esclerosis 
múltiple” plus “Latin America” and all country names. Full articles or abstracts from 
meetings reporting original research on cost or economic analyses, budget impact 
or resource utilization were obtained. No restrictions were placed on publication 
date or language. All work was done in duplicate by two independent reviewers 
with adjudication by consensus discussion. Results: We identified 1482 papers, 
of which 27 were considered for analysis. There were 7 economic analyses (5 cost-
effectiveness, 2 cost-utility), 5 budget impact analyses, 10 cost analyses (6 drug 
expenditures and 4 cost of illness), 4 on resource utilization and 1 on productivity 
loss. Studies were obtained from 5 countries (18 Brazil, 3 Argentina, 3 Colombia, 2 
Mexico, 1 Chile). Mostly (22/27, 81%) were published as abstracts; 5 were published 
as full text articles (19%). Dates for these publications ranged from 2002 to 2013, 
with an exponential increase over time. The number of MS patients is increasing 
rapidly (71% increase in Brazil between 2006 and 2009). However, hospitalization 
rates (overall and per patient) have been decreasing, as newer more effective drugs 
have been increasingly used. Disease modulating therapies are predominantly 
used. Costs of care are quite high and have risen dramatically, e. g. > 200% in Brazil 
between 2007-2012, with beta-interferons mostly used (78%). Some high cost drugs 
such as fingolimod and natalizumab have been found cost-effective over older drugs 
such as beta-interferons or glatiramer acetate in Mexico, Brazil and Colombia, with 
modest impact on budgets. ConClusions: Very little evidence related to cost of 
MS has been produced in Latin America. More research is needed to better support 
decisions regarding care of MS patients.
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Alzheimer’s DiseAse: meDicAtioN costs AND imPAct of GeNeric 
substitutioN
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
objeCtives: Alzheimer’s disease has a substantial economic impact on patients, 
their caregivers and society. There are four cognitive enhancers commonly used in 
the treatment of Alzheimer’s disease: three cholinesterase inhibitors (donepezil, 
rivastigmine and galantamine) and one NMDA receptor antagonist (memantine). 
Studies have indicated that the cost of cholinesterase treatment may be offset by 
savings in other health care costs. Methods: The cost of medication on the South 
African market for Alzheimer’s disease was analysed using June 2014 retail prices 
with the Defined Daily Dose (DDD) as unit cost indicator. A retrospective drug uti-
lisation study was conducted on prescription data of a medical insurance scheme 
administrator for 2012. Results: The cost per DDD for memantine was R26.20 
(20 mg, two 10 mg tablets). For rivastigmine, the cost was R41.02 per DDD and for 
galantamine R27.72 per DDD (using the most convenient dosage strengths). These 
three products were all originator products. For donepezil, the originator and three 
branded generics were available. The cost of the originator was R27.86 per DDD, and 
for all three generics R16.29 per DDD. Only 32 patients were included in the drug 
utilisation study since not all medical aids reimburse these products. The aver-
age age of patients was 74.17 (SD= 9.54) years, with 50% females. Only memantine 
and donepezil were prescribed. Donepezil accounted for 77.48% of prescriptions 
(of which 60.93% were generic prescriptions). The average Prescribed Daily Doses 
(PDDs) were 16.30 (SD= 4.92) mg for memantine and 8.73 (SD= 2.84) mg for donepezil. 
The most frequent PDDs for memantine was 20 mg (62.96% of prescriptions) and 
10 mg (37.04% of prescriptions), and for donepezil 10 mg (65.96% of prescriptions) 
and 5 mg (29.79% of prescriptions). ConClusions: More South African studies on 
Alzheimer’s disease treatment cost are needed that include the stage of the disease 
and adherence to treatment.
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costs AssociAteD with the use of eNzyme-iNDuciNG ANti-ePilePtic 
DruGs Versus NoN-eNzyme-iNDuciNG ANti-ePilePtic DruGs:  
A systemAtic reView
Xiong T.1, Gallagher E.2, MacGilchrist K.S.1, Thieffry S.2
1Abacus International, Oxfordshire, UK, 2UCB Pharma, Brussels, Belgium
objeCtives: Several commonly prescribed enzyme-inducing anti-epileptic drugs 
(EIAEDs) stimulate the synthesis of some hepatic enzymes responsible for drug 
metabolism. This synthesis can lead to complications by altering endogenous 
metabolic pathways or by affecting the elimination of concomitant drugs thus 
increasing health care costs. This study aimed to systematically review published 
estimates of direct and indirect costs associated with the use of EIAEDs compared 
with non-enzyme-inducing anti-epileptic drugs (nEIAEDs) in patients with focal 
and generalised seizures, and to evaluate methodological differences between the 
studies. Methods: Comprehensive electronic searches were undertaken using 
MEDLINE, EMBASE, Cochrane Library, EconLit, relevant conference proceedings 
and cost effectiveness analysis registries. All studies reporting any direct and 
indirect costs of AEDs for the treatment of patients with epileptic seizures were 
included. Study quality assessment was performed for every included study 
using a predesigned check list. Results: Thirty-seven full-length articles and 
two abstracts reporting costs were reviewed. Two studies reported AED costs, 
drug-specific adverse event costs and non-drug health care costs subsequent to 
the initiation of each individual AED (medical visits, MRI scans, etc.). Six studies 
reported specific AED costs and the overall subsequent non-drug health care cost 
without stratification by event. Eighteen studies reported AED acquisition costs 
but did not report any other subsequent AED-related health care costs stratified 
by treatment. Thirteen studies reported the whole cost of illness with only a list 
of AEDs included. To date, no study has been specifically designed to compare 
the total costs between EIAED and nEIAED use, although some studies compared 
direct and indirect costs of several newer AEDs versus older AEDs. ConClusions: 
Insufficient data and heterogeneity in methodology prevent valid comparisons 
being made between the total cost of EIAEDs and nEIAEDs. More research is 
required to identify if meaningful differences in the total cost of treatment exist 
between EIAEDs and nEIAEDs.
This analysis aimed to assess if the early switch from IFNB to fingolimod impacts 
MS clinical outcomes and promotes better resource utilization in a Portuguese 
hospital perspective. Methods: This analysis was based on TRANSFORMS phase 
III trial extension data. A cost-effectiveness model was developed to calculate the 
cost per relapse avoided with 4.5 years of continuous treatment with fingolimod 
(early treatment) versus 1 year of treatment with IFNB followed by a 3.5 years of 
treatment with fingolimod (delayed treatment). A Portuguese hospital perspec-
tive was adopted addressing only direct costs: drug, monitoring and relapses’ 
treatment. Drug costs were based on Portuguese list prices, while the unit cost 
of each complication was obtained from the Diagnosis Related Groups tariff. The 
costs of relapses were derived from the Portuguese literature. Results: Assuming 
there are 819 patients treated with IFNB that are poor responders, the early treat-
ment with fingolimod resulted in more relapses avoided when compared with 
delayed treatment with fingolimod (2,211 versus 1,843). The early treatment with 
fingolimod led to an increase of drug acquisition costs, but reduced costs asso-
ciated to monitoring and relapses’ treatment. The total costs were 86,380,820€ 
for early treatment versus 79,257,091€ for delayed treatment. This represents an 
average incremental investment of 1,933€ per patient per year. The early strategy 
resulted an incremental cost effectiveness ratio of 19,358€ per relapse avoided 
when compared with the delayed strategy. ConClusions: Under the Portuguese 
hospital perspective, early treatment with fingolimod is expected to result in 
better clinical outcomes associated with a more efficient health care resources 
allocation.
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cost ANAlysis of two AftercAre strAteGies iN chroNic coNtiNuous 
iNtrAthecAl bAclofeN therAPy iN PAtieNts with iNtrActAble 
sPAsticity
Burgers L.T.1, Goslinga-van der Gaag S.M.E2, Delhaas E.M.2, Redekop W.K.3
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus Medical Center, 
Rotterdam, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands
objeCtives: Intrathecal baclofen (ITB) therapy is indicated for use in the manage-
ment of intractable spasticity. Patients treated with ITB are required to receive a 
pump refill at least once every three months in the hospital (standard care (SC)). 
Since SC can be very burdensome for both patients and informal caregivers, an 
alternative approach (Care4homecare) has been developed which enables patients 
to receive pump refills at home. Moreover, the use of specially trained nurse prac-
titioners ensures that there is no reduction in effectiveness. We compared the 
costs of both strategies. Methods: Resource use in both strategies was estimated 
using observational data of 38 adult patients with spasticity (due to e. g. multiple 
sclerosis or spinal cord injury) that are currently living at home. We then com-
bined this data with expert opinion and the Dutch costing manual to estimate 
the total one-year costs from a societal perspective. Results: Patients included 
in the analysis had on average an age of 52±14.4 years, 50% was men and patients 
scored on average 44±12.5 points on the Care Dependency Scale. The Care4homecare 
strategy involves care that is almost identical to SC and therefore can result in 
comparable direct medical costs. However, patients receiving Care4homecare do 
not incur any travel costs compared with SC patients (€ 489). In addition, the pro-
ductivity costs of informal caregivers (SC € 195; Care4homecare € 40) and of patients 
treated with Care4homecare are less than the costs of patients receiving SC. From 
a societal perspective, the total costs of Care4homecare can be lower than that of 
SC. ConClusions: Care4homecare is an alternative approach to treat patients 
with intrathecal baclofen that can be cost-neutral from a health care sector per-
spective and cost-saving from a societal perspective. Moreover, it can be a welcome 
option for many patients and caregivers who want to avoid the burden of regular 
hospital visits.
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cost ANAlysis of the use of GlAtirAmer AcetAte comPAreD to 
iNterferoN-Â iN PAtieNts with relAPsiNG-remittiNG multiPle 
sclerosis AND sPAsticity iN sPAiN
Sanchez de la Rosa R.1, Garcia Bujalance L.2, Meca Lallana J.3
1Teva Pharma, Madrid, Spain, 2Teva Pharmaceuticals, Madrid, Spain, 3Virgen de la Arrixaca 
Hospital, Murcia, Spain
objeCtives: To analyze the costs associated with first-line use of glatiramer acetate 
(GA) compared to interferon-B (INF-β ) in patients with relapsing-remitting multiple 
sclerosis (RRMS) and spasticity from the perspective of the National Health System 
of Spain. Methods: A cost analysis of treatment and spasticity management with 
INF-β compared to GA for 6 months were analyzed. The clinical data were taken from 
the ESCALA study, which showed an improvement in spasticity in terms of spasm 
frequencies, muscle tone, and pain 3 and 6 months after the start of GA therapy. 
Unit costs for the resources used were taken from the BOTPLUS 2.0 database and 
available literature. The cost analysis is expressed in euros as of 2014, and a price 
discount of 7.5% was applied as set forth in Spanish Royal Decree 8/2010. Results: 
The costs associated with the management of RRMS, spasticity, and relapses using 
GA and INF-β were € 4,671.31 and € 7,078.02, respectively, generating a cost savings 
of € 2,406.72/patient, in favour of GA. ConClusions: The use of AG in the first-
line treatment of patients with RRMS not only improves spasticity but it could be 
a strategy that offers savings cost after 6 months from the start of treatment. To 
initiate the treatment with AG and keep it in patients with optimal response would 
be a more efficient treatment option than INF-β .
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systemAtic reView of the ecoNomics of multiPle sclerosis iN lAtiN 
AmericA
Einarson T.R.1, Bereza B.1, Machado M.2
1University of Toronto, Toronto, ON, Canada, 2Biogen Idec, São Paulo, Brazil
objeCtives: To summarize published articles dealing with economic issues related 
to multiple sclerosis (MS) in Latin America. Methods: We searched Medline, 
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21.91%, p< 0.01), compared to those without a PD diagnosis. The PD cohort also 
incurred significantly higher skilled nursing facility ($6,458 vs. $5,182, p= 0.03), DME 
($344 vs. $206, p< 0.01) and pharmacy costs ($6,025 vs. $4,998, p< 0.0001) compared 
to the comparison cohort. ConClusions: Study results suggest that patients 
diagnosed with PD incurred significantly higher costs and had higher resource 
utilization than those without a PD diagnosis.
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relAtioNshiP betweeN the Direct meDicAl costs AND Direct  
NoN-meDicAl costs of PArkiNsoN’s DiseAse AccorDiNG to  
DiseAse seVerity DuriNG 4 yeArs of follow-uP iN sPAiN
Martinez P.1, Rodriguez-Blazquez C.1, Paz S.2, Lizán L.3, Forjaz M.J.4, Frades B.5, Moreno R.6
1National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain, 
2Outcomes’10, Castellon, Spain, 3Outcomes 10, Castellon, Spain, 4National School of Public Health 
and REDISSEC, Carlos III Institute of Health, Madrid, Spain, 5Alzheimer Center Reina Sofia 
Foundation, Carlos III Institute of Health, Madrid, Spain, 6Infanta Cristina Hospital, Madrid, Spain
objeCtives: To describe the medical and non-medical direct costs of PD in rela-
tion to the total direct cost and its variation with disease severity during 4 years 
of follow-up. Methods: A descriptive, observational, longitudinal study in PD 
patients belonging to the ELEP study (2007-2010). Data on disease severity and use 
of resources were collected for three consecutive months, yearly, for 4 years. Direct 
medical (funded medical equipment, medications and medical assistance) and 
direct non-medical costs (alternative care, home assistance, non-funded medical 
equipment and medications) for 4 years depending on severity by Hoehn and Yahr 
(HY) was described. Costs were estimated by multiplying rates obtained from the 
database Oblikue (http://www.oblikue.com) and pharmacy costs from the BotPlus 
Web (https://botplusweb.portalfarma.com) by the number of resources used, 
updated to Spanish € , 2012. Results: 198 patients were included. Average age: 
63±11 years, 50% male, mean PD duration of 8±6 years. Mild (HYI-II) and moderate 
(HYIII) PD varied from 76% and 21% to 64% and 29%, respectively during follow-up. 
Total direct cost was higher in severe stages, being in year 4, € 1,477.32 HYI (95%CI: 
219.55-2,735.10) and € 3,606.66 HYIV (95%CI: 893.97-6,319.35) compared to year 1, 
€ 1,093.32 HYI (95%CI: 624.99-1,561.65) to € 2,656.27 HYIV (95%CI: -53.14-5,365.68). 
Direct medical costs ranged from € 886.62 (95%CI: 475.13-1,298.11) HYI and € 2,376.30 
HYIV (95%CI: -53.12-4,805.73) in year 1 to € 909.96 HYI (95%CI: 942.43-1,327.49) and 
€ 2,768.49 HYIV (95%CI: 34.21-5,502.76) at year 4. Direct non-medical cost variation 
were determined by PD temporal evolution, increasing between year 1 and 4 within 
each stage, € 723.47 to € 4,255.20 HYI and € 653.27 to € 1,676.35 HYIV. ConClusions: 
The economic burden of PD rises with duration and severity of the disease, progres-
sively increasing the direct, medical and non-medical costs. Besides to improve 
patients’ HRQoL, therapies aimed at controlling the symptoms severity will favor a 
more efficient management of the disease.
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Does curreNt PortuGuese fiNANciNG moDel for multiPle sclerosis 
coVers for estimAteD NeeDs?
Montóia B.1, Guerreiro T.1, Viana R.2
1Novartis Farma – Produtos Farmaceuticos S. A., Porto Salvo, Portugal, 2Novartis Farma-Produtos 
Farmacêuticos S. A., Portugal, Porto Salvo, Portugal
objeCtives: Portuguese financing model set for Multiple Sclerosis (MS) establishes 
a comprehensive price of 1.031,65€ per remitting patient/month. This study aimed 
to estimate global and individual direct costs of MS in Portugal and evaluate the 
coverage of MS Financing model for Relapsing-Remiting Multiple Sclerosis (RRMS) 
patients. Methods: A cost-of-illness (COI) approach was taken to assess direct 
costs/per RRMS patient by EDSS level, both for remission and relapse status using 
Delphi methodology for clinical practice measurement. Portuguese epidemiological 
data available for prevalence and relative distribution by EDSS level was used to 
estimate global MS costs and an average cost per RRMS patient. Results: The global 
cost for RRMS in Portugal is estimated to be approximately 83M€ /year for patients 
treated with 1st line Disease Modifying Therapies (DMT). Relapse treatment costs 
account for 8M€ . Direct costs estimated per disability level show that disability 
levels are directly related with expenditure in RRMS patients in remission (EDSS≤ 3: 
10.754,90€ ; 3,5≤ EDSS≤ 4,5: 20.113,99€ ; 5≤ EDSS≤ 6: 21.170,36€ ; EDSS≥ 6,5: 24.945,94€ ). 
The same was observed for relapse cost (EDSS≤ 3: 4.952,23€ ; 3,5≤ EDSS≤ 4,5: 5.568,49€ ; 
5≤ EDSS≤ 6: 8.801,03€ ; EDSS≥ 6,5: 9.265,31€ ). An average cost of 14.563,48€ per 
RRMS patient was estimated based on Portuguese EDSS epidemiological distribu-
tion. ConClusions: Current comprehensive financing model per patient does 
not cover the costs associated with an average RRMS patient. We demonstrated 
that considering the epidemiological distribution per EDSS level there is a gap of 
2.183,68€ (14.563,48€ vs. 12.379,80€ ). In addition, it was estimated that 2nd line high 
efficacy treatments (additional investment of 76% in treatment costs) may lead up to 
4.3M€ savings in relapse treatment total costs by reducing annualized relapse rate. 
Further studies should be developed to assess the budget impact of 2nd line high 
efficacy treatments on disability progression since lower EDSS scales are associated 
with less expenditure per patient (EDSS≤ 3: 10.754,90€ vs EDSS ≥ 6,5: 24.945,94€ ).
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PhArmAcoecoNomic AsPects of multiPle sclerosis treAtmeNts iN 
irAN
Khanizadeh H.1, Izham M.2, Nikkhah K.3
1UNIVERSITY SAINS MALAYSIA, Penang, Malaysia, 2Universiti Sains Malaysia, Pinang, Palau 
Pinang, Malaysia, 3Mashhad University of Medical Sciences, Mashhad, Khorasan, Iran
objeCtives: Multiple Sclerosis (MS) is a chronic and progressive which represents 
a catastrophic payment to patient, society and health care system. Iran, differing 
to the other countries in Middle- east, is considered to have a medium to high 
prevalence of MS. Although much is known about the MS cost in the world, there 
is a very paucity of the MS cost study in Iran. The aim of study was to estimate the 
costs and QOL in MS individuals and determine whether these costs increase as 
disability progress. Methods: We studied 160 MS patients who attended in the MS 
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PhArmAcoecoNomic stuDy of botuliNium toxiN tyPe A iN treAtmeNt 
of Post-stroke sPAsticity iN the russiAN feDerAtioN:  
cost-effectiVeNess ANAlysis
Yagudina R., Kulikov A., Ugrekhelidze D.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To assess the cost-effectiveness of abobotulinumtoxinA, onabotuli-
numtoxinA, incobotulinumtoxinA and local standard therapy (oral muscle relaxers) 
in patients with post-stroke spasticity in Russia for 1-year period. Physical therapy 
was used in all therapy schemes. Methods: A decision tree was used to simulate 
the effects of abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA and 
standard therapy. The data on drugs efficacy (measured as decrease in the Modified 
Ashworth scale (MAS) score) was obtained from available clinical trials [1-3]. The fol-
lowing costs were taken into account:, the costs of BTA and other drugs, costs of inpa-
tient and outpatient care in the Russian Federation, costs of adverse events, disability 
pensions, GDP loss due to post-stroke spasticity. Costs of BTA and other drugs were 
taken from the essential drug list and the database of drugs prices. Medical care costs 
were estimated from the Standard of treatment of stroke consequences developed by 
Ministry of Health of the Russian Federation. Costs of adverse events were calculated 
basing on Russian clinical guidelines and database of drugs prices. Disability pen-
sions were taken from Russian Pension Fund database. GDP loss was based on the 
GDP information from World Bank. Cost-effectiveness ratio (CER) of BTA and stand-
ard therapy was calculated and compared in four treatment schemes. Results: 
Therapy with abobotulinumtoxinA showed most prominent decrease of Modified 
Ashworth score equal to 1,67, as for onabotulinumtoxinA – 1,17, incobotulinum-
toxinA – 0,87, standard therapy – 0,67. The calculated CER in USD per 1 spastic-
ity decrease point according to MAS was lowest for abobotulinumtoxinA (389524 
RUB/11356 $) in comparison with onabotulinumtoxinA (635631 RUB/18532 $); inco-
botulinumtoxinA (798750 RUB/23287 $) and standard therapy (873312 RUB/25461 $). 
ConClusions: Therapy conversion to abobotulinumtoxinA comparing with stand-
ard therapy, onabotulinumtoxinA and incobotulinumtoxinA was associated with 
decrease of spasticity. Transfer to abobotulinumtoxinA is considered cost-effective 
in patients with post-stroke spasticity, given a cost-effectiveness ratio 389524 
RUB/11356 $.
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cost comPArisoN of DeeP DrAiN stimulAtioN (Dbs) AND coNtiNueD 
subcutANeous APomorPhiNe iNfusioN (csAi) iN PAtieNts with 
ADVANceD PArkiNsoN’s DiseAse
Walleser Autiero S.1, Eggington S.1, Valyi A.2
1Medtronic International Trading Sarl, Tolochenaz, Switzerland, 2Medtronic Ltd UK & Ireland, 
Watford, UK
objeCtives: Deep Brain Stimulation (DBS) for the treatment of advanced 
Parkinson’s Disease (PD) is a therapy supported with high level evidence, however 
no direct comparative studies exist of DBS against other therapy options, such as 
continued subcutaneous apomorphine infusion (CSAI) exists. The objective of this 
study was to evaluate the 5-year cost profiles of two therapies for advanced PD, DBS 
and CSAI, from a UK payer perspective. Methods: A Markov model, previously used 
to model cost-effectiveness of DBS+BMT vs BMT alone (Eggington 2013), served to 
evaluate the cost profile of DBS and CSAI over five-years. Equal efficacy of the two 
therapies was assumed. The cost analysis covered: device acquisition, implanta-
tion, adverse event management, concomitant drug use, device replacements and 
follow-up. Cost data were taken from UK national tariffs, combined with device/
drug price lists and data from previous economic studies of interventions for PD. 
Disease-related inputs were based on recent studies of DBS and CSAI in patients 
with advanced PD, plus long-term data from the literature. Costs were discounted 
at 3.5% per annum. Results: Total discounted costs over 5 years were £69,566 and 
£80,843 for DBS and CSAI, respectively, leading to cost savings of £11,277 of DBS 
compared to CSAI over 5 years. DBS is cost saving compared to CSAI from 3 years 
onwards, with the initial costs of DBS device acquisition shown to be offset by the 
on-going provision of CSAI. ConClusions: The results indicate that DBS requires 
less health care resources than CSAI over five-years. Comparative clinical data are 
needed to formally assess the relative cost-effectiveness of the two interventions.
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retrosPectiVe ANAlysis of the ecoNomic burDeN of u. s. loNG-term 
cAre fAcility resiDeNts DiAGNoseD with PArkiNsoN’s DiseAse
Huang A.1, Shrestha S.1, Baser O.2, Wang L.1
1STATinMED Research, Plano, TX, USA, 2STATinMED Research and The University of Michigan, 
Ann Arbor, MI, USA
objeCtives: To examine the health care utilizations and costs of long-term care 
facility patients diagnosed with Parkinson’s disease (PD). Methods: Patients 
diagnosed with PD (International Classification of Disease, 9thRevision, Clinical 
Modification [ICD-9-CM] diagnosis code 332) were identified using the Minimum 
Data Set (MDS) linked to 5% Medicare data from 01JAN2009 through 31DEC 2010. 
The initial diagnosis date was designated as the index date. A comparison cohort 
was created for patients without a PD diagnosis, using 1: 1 propensity score match-
ing (PSM) to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date for the comparison group was randomly 
chosen to reduce selection bias. Patients in both cohorts were required to be at 
least age 65 years, have at least two consecutive quarterly assessments in MDS 
data in the 6 months prior to the index date, and have continuous medical and 
pharmacy benefits 1 year before and after index date. Study outcomes, (health 
care costs and utilizations) were compared between the disease and comparator 
cohorts, based on the matched sample. Results: After applying PSM, a total of 
986 patients were included in each group (diseased and comparator cohorts), and 
baseline characteristics were balanced. A higher percentage of patients with PD 
had inpatient admissions (35.09% vs. 30.32%, p= 0.02), outpatient visits (93.91% 
vs. 89.45%, p< 0.001) and durable medical equipment (DME) utilization (27.69% vs. 
